IRIS
BUTTARI, FABIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.794
AS - Asia 2.198
EU - Europa 1.676
SA - Sud America 392
AF - Africa 32
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 8
Totale 18.109
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.738
SG - Singapore 1.052
IT - Italia 468
CN - Cina 363
BR - Brasile 347
HK - Hong Kong 252
KR - Corea 240
IE - Irlanda 231
DE - Germania 199
UA - Ucraina 135
RU - Federazione Russa 117
GB - Regno Unito 106
VN - Vietnam 91
FR - Francia 74
PL - Polonia 74
FI - Finlandia 58
SE - Svezia 53
NL - Olanda 40
CA - Canada 39
IN - India 28
JP - Giappone 25
BE - Belgio 22
AR - Argentina 20
AT - Austria 20
ID - Indonesia 20
CZ - Repubblica Ceca 18
BD - Bangladesh 16
TR - Turchia 16
ES - Italia 14
IQ - Iraq 14
UZ - Uzbekistan 14
ZA - Sudafrica 13
RO - Romania 11
CO - Colombia 8
EU - Europa 8
PK - Pakistan 8
MA - Marocco 7
MX - Messico 7
IR - Iran 6
LT - Lituania 6
PY - Paraguay 6
SA - Arabia Saudita 6
AU - Australia 5
CL - Cile 5
HR - Croazia 5
PH - Filippine 5
AE - Emirati Arabi Uniti 4
DK - Danimarca 4
GR - Grecia 4
IL - Israele 4
KG - Kirghizistan 4
KZ - Kazakistan 4
MY - Malesia 4
AL - Albania 3
BN - Brunei Darussalam 3
CH - Svizzera 3
DM - Dominica 3
EC - Ecuador 3
KE - Kenya 3
OM - Oman 3
RS - Serbia 3
AZ - Azerbaigian 2
EG - Egitto 2
HN - Honduras 2
JM - Giamaica 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
NG - Nigeria 2
NO - Norvegia 2
PT - Portogallo 2
TN - Tunisia 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BG - Bulgaria 1
BO - Bolivia 1
CG - Congo 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
HU - Ungheria 1
JO - Giordania 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
MU - Mauritius 1
NP - Nepal 1
NR - Nauru 1
NZ - Nuova Zelanda 1
PA - Panama 1
PW - Palau 1
QA - Qatar 1
SI - Slovenia 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
VE - Venezuela 1
Totale 18.109
Salva come PNG Salva come JPEG
Città #
Wilmington 3.465
Houston 3.221
Woodbridge 2.678
Singapore 541
Chandler 536
Fairfield 497
Ashburn 305
Ann Arbor 283
Hong Kong 232
Dublin 199
Seattle 196
New York 174
Dallas 173
Beijing 171
Cambridge 167
Rome 146
Medford 131
The Dalles 128
Santa Clara 95
Jacksonville 90
Dearborn 80
Los Angeles 78
Lawrence 63
Council Bluffs 54
Munich 54
Kraków 52
Buffalo 50
São Paulo 43
Zhengzhou 43
Ho Chi Minh City 30
Milan 29
Chicago 24
Hanoi 24
London 24
Moscow 24
Palo Alto 24
San Diego 24
Philadelphia 23
Brussels 22
Norwalk 22
Tokyo 22
San Jose 21
Warsaw 20
Brooklyn 19
Columbus 19
Redondo Beach 19
Southern 19
Jakarta 18
Brno 16
Lappeenranta 16
Seoul 16
Menlo Park 15
Redwood City 15
Boston 14
Montreal 14
Chennai 13
Denver 13
Roebling 13
Arosio 12
Nanjing 12
Tampa 12
Naples 11
Nuremberg 11
Rio de Janeiro 11
Toronto 11
Belo Horizonte 10
Helsinki 10
Johannesburg 10
Guangzhou 9
San Francisco 9
Atlanta 8
Center 8
Colorado Springs 8
Elk Grove Village 8
Falls Church 8
Inverigo 8
Orem 8
Poplar 8
Stockholm 8
Turku 8
Ankara 7
Bologna 7
Catania 7
Detroit 7
Hefei 7
Mountain View 7
Nanchang 7
Guarulhos 6
Hangzhou 6
Kunming 6
Paris 6
Perugia 6
Salt Lake City 6
Shanghai 6
Tashkent 6
Vienna 6
Amsterdam 5
Bari 5
Frankfurt am Main 5
Hounslow 5
Totale 14.848
Salva come PNG Salva come JPEG
Nome #
Neurophysiology of synaptic functioning in multiple sclerosis 548
miR-142-3p Is a Key Regulator of IL-1β-Dependent Synaptopathy in Neuroinflammation 504
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration 500
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML 494
Growth factors and synaptic plasticity in relapsing-remitting multiple sclerosis 482
TRPV1 polymorphisms and risk of interferon β-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis 479
Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads 470
Abnormal cervical lymph nodes in multiple sclerosis: a preliminary ultrasound study 460
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis 455
Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis 445
Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53 444
Determination of κFLC and κ Index in cerebrospinal fluid: a valid alternative to assess intrathecal immunoglobulin synthesis 444
CB1 receptor affects cortical plasticity and response to physiotherapy in multiple sclerosis 440
Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances 434
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 418
Epstein-Barr virus genetic variants are associated with multiple sclerosis 415
Nerve growth factor is elevated in the CSF of patients with multiple sclerosis and central neuropathic pain 408
From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study 395
Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis 387
Association between a genetic variant of type-1 cannabinoid receptor and inflammatory neurodegeneration in multiple sclerosis 384
Treatment options to reduce disease activity after natalizumab: paradoxical effects of corticosteroids 381
Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems 378
Reversible hyporegenerative anemia during natalizumab treatment 374
Remodeling functional connectivity in multiple sclerosis: A challenging therapeutic approach 348
Dimethyl fumarate vs. fingolimod in multiple sclerosis: an independent, multi-centre, real world, quasi-randomized study 332
Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course 332
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 312
Tumor Necrosis Factor and Interleukin-1β Modulate Synaptic Plasticity during Neuroinflammation 310
Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis 303
Transient Receptor Potential Vanilloid 1 Modulates Central Inflammation in Multiple Sclerosis 295
TRPV1 channels regulate cortical excitability in humans 293
Oral D-Aspartate enhances synaptic plasticity reserve in progressive multiple sclerosis 283
The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis 267
Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive Functions 251
Exploiting the multifaceted effects of cannabinoids on mood to boost their therapeutic use against anxiety and depression 251
Treatment with Dimethyl Fumarate Enhances Cholinergic Transmission in Multiple Sclerosis 180
Peripheral T cells from multiple sclerosis patients trigger synaptotoxic alterations in central neurons 175
Prototypical proinflammatory cytokine (IL-1) in multiple sclerosis: role in pathogenesis and therapeutic targeting 173
Multiple Sclerosis: kFLC index values related to gender 158
MiR-142-3p is a Critical Modulator of TNF-mediated Neuronal Toxicity in Multiple Sclerosis 154
Modeling Resilience to Damage in Multiple Sclerosis: Plasticity Meets Connectivity 150
Emerging Role of Extracellular Vesicles in the Pathophysiology of Multiple Sclerosis 133
Exercise protects from hippocampal inflammation and neurodegeneration in experimental autoimmune encephalomyelitis 130
Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression 127
Inflammation-Associated Synaptic Alterations as Shared Threads in Depression and Multiple Sclerosis 126
Re-Examining the Role of TNF in MS Pathogenesis and Therapy 122
Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis 118
IL-6 in the Cerebrospinal Fluid Signals Disease Activity in Multiple Sclerosis 111
The BDNF Val66Met Polymorphism (rs6265) Modulates Inflammation and Neurodegeneration in the Early Phases of Multiple Sclerosis 105
A novel POLR3A genotype leads to leukodystrophy type-7 in two siblings with unusually late age of onset 102
Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients 101
MiR-142-3p regulates synaptopathy-driven disease progression in multiple sclerosis 95
Corrigendum: Inflammation-Associated Synaptic Alterations as Shared Threads in Depression and Multiple Sclerosis 94
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 93
Cerebrospinal fluid levels of L-glutamate signal central inflammatory neurodegeneration in multiple sclerosis 91
A single nucleotide ADA genetic variant is associated to central inflammation and clinical presentation in MS: implications for cladribine treatment 87
Age at disease onset associates with oxidative stress, neuroinflammation, and impaired synaptic plasticity in relapsing-remitting multiple sclerosis 86
Interleukin-1β alters hebbian synaptic plasticity in multiple sclerosis 83
A large family with p.Arg554His mutation in ABCD1: clinical features and genotype/phenotype correlation in female carriers 83
Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential 83
Cerebrospinal fluid, brain, and spinal cord levels of L-aspartate signal excitatory neurotransmission abnormalities in multiple sclerosis patients and experimental autoimmune encephalomyelitis mouse model 82
Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis 76
COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab 75
Interleukin-10 contrasts inflammatory synaptopathy and central neurodegenerative damage in multiple sclerosis 71
Inflammation and Corticospinal Functioning in Multiple Sclerosis: A TMS Perspective 69
Decipher non-canonical SPAST splicing mutations with the help of functional assays in patients affected by spastic paraplegia 4 (SPG4) 68
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 66
The microRNA let-7b-5p Is Negatively Associated with Inflammation and Disease Severity in Multiple Sclerosis 66
Interleukin 6 SNP rs1818879 Regulates Radiological and Inflammatory Activity in Multiple Sclerosis 64
Genetic regulation of IL-8 influences disease presentation of multiple sclerosis 63
Preventive exercise attenuates IL-2-driven mood disorders in multiple sclerosis 59
Osteopontin Is Associated with Multiple Sclerosis Relapses 58
Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing-Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study) 58
Cortical plasticity in AQP4-positive NMOSD: a transcranial magnetic stimulation study 56
Mood disturbances in newly diagnosed Parkinson's Disease patients reflect intrathecal inflammation 56
BACE1 influences clinical manifestations and central inflammation in relapsing remitting multiple sclerosis 56
Preventive exercise and physical rehabilitation promote long-term potentiation-like plasticity expression in patients with multiple sclerosis 55
Homeostasis of serine enantiomers is disrupted in the post-mortem caudate putamen and cerebrospinal fluid of living Parkinson's disease patients 54
Distinct intrathecal inflammatory signatures following relapse and anti-COVID-19 mRNA vaccination in multiple sclerosis 54
An IL-5 Single-Nucleotide Polymorphism Influences Neuroinflammation and Prospective Disease Activity in Multiple Sclerosis 54
Physical exercise and synaptic protection in human and pre-clinical models of multiple sclerosis 53
Fatigue in Multiple Sclerosis Is Associated with Reduced Expression of Interleukin-10 and Worse Prospective Disease Activity 53
Interleukin-9 protects from microglia- and TNF-mediated synaptotoxicity in experimental multiple sclerosis 53
Low-contrast visual acuity test is associated with central inflammation and predicts disability development in newly diagnosed multiple sclerosis patients 50
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 48
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of Frailty 44
Inflammatory signature in amyotrophic lateral sclerosis predicting disease progression 43
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders 41
Interaction between miR-142-3p and BDNF Val/Met Polymorphism Regulates Multiple Sclerosis Severity 36
Maresin-1 promotes neuroprotection and prevents disease progression in experimental models of multiple sclerosis through metabolic reprogramming and shaping innate and adaptive disease-associated cell types 32
Topographical Correlation between Structural and Functional Impairment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes with a History of Optic Neuropathy 32
Structural and Functional Assessment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes Without History of Optic Neuropathy 28
New variants and genotype–phenotype correlation in KIF5A mutation: the contribution of a large Italian cohort 13
IL-1β contributes to neurological disability in NMOSD AQP4 + Patients 10
Maresin-1 promotes neuroprotection and modulates metabolic and inflammatory responses in disease-associated cell types in preclinical models of multiple sclerosis 8
Cladribine tablets in the new multiple sclerosis era 8
MicroRNA-142-3p shuttling in extracellular vesicles marks regulatory T cell dysfunction in multiple sclerosis 7
Effect of Anodal Transcranial Direct Current Stimulation on the Intensity of Post-dural Puncture Headache: Results of Two Randomized Sham Controlled Trials 7
Totale 18.502
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.384
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.384
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.279 0 0 0 0 0 283 459 294 71 70 72 30
2021/2022705 34 32 16 41 3 128 30 34 78 89 33 187
2022/20231.305 136 117 111 202 73 282 86 63 102 14 60 59
2023/2024535 85 20 22 29 39 121 28 40 25 26 21 79
2024/20252.215 86 428 169 94 143 217 179 105 212 267 168 147
2025/20261.802 328 187 531 273 369 114 0 0 0 0 0 0
Totale 18.502